Loading
Normalising the tumour's blood vessels lets immune cells in, and VEGF blockade removes an immunosuppressive signal.
This combination pairs Immune checkpoint inhibitors with Anti-angiogenic therapy against VEGF. VEGF suppresses dendritic cell maturation, promotes Tregs and MDSCs and produces leaky vessels that block T-cell infiltration, so normalising the vessels lets immune cells in and removes an immunosuppressive signal, linking the VEGF angiogenesis and PD-1 / PD-L1 immune checkpoint pathways. It is standard in Renal cell carcinoma (pembrolizumab-axitinib, nivolumab-cabozantinib), Hepatocellular carcinoma (atezolizumab-bevacizumab) and Endometrial cancer (lenvatinib-pembrolizumab), on multiple phase 3 trials with overall survival benefit. Ivonescimab fuses both functions into one molecule and beat pembrolizumab in Non-small-cell lung cancer.
Shares Ivonescimab, Anti-angiogenic therapy, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Atezolizumab, Anti-angiogenic therapy, Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Ivonescimab, Anti-angiogenic therapy, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Lenvatinib + pembrolizumab (pMMR endometrial cancer after platinum), Anti-angiogenic therapy, Endometrial cancer, Pembrolizumab.
Shares Atezolizumab, Anti-angiogenic therapy, Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Ivonescimab, Anti-angiogenic therapy, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Ivonescimab, Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Ivonescimab, Anti-angiogenic therapy, Immune checkpoint inhibitors, Non-small-cell lung cancer.